Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…
Abstract Number: 1495 • ACR Convergence 2025
Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
Livie Timmerman¹, Melissa Mannion² and Emily Smitherman², ¹University of Alabama at Birmingham, Gardendale, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Physician Global Assessment (PGA) is used to measure disease activity on a 0–10 scale for many pediatric rheumatic conditions. However, the thresholds at…
Abstract Number: 1478 • ACR Convergence 2025
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Bin Zhou¹, QIn Huang², Pan Wang³ and Qiguo Cui⁴, ¹Nanfang Hospital, Guangzhou, Guangdong, China (People's Republic), ²Nanfang Hospital, Guangzhou, China (People's Republic), ³southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ⁴Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…
Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Martha Rodriguez¹, Ekemini Ogbu², Ashley Danguecan³, Marietta De Guzman⁴, Alexandra Theisen⁵, Lawrence Ng⁶, Andrea Knight³ and Ryann Kammeyer⁷, ¹Riley Hospital For Children at Indiana University, Indianapolis, IN, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Arkansas, Little Rock, AR, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Colorado, Denver, CO
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 1044 • ACR Convergence 2025
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Gunjan Rana¹, Mansi Mehta¹ and Joanne Cunha², ¹Saint Vincent Hospital, Worcester, MA, ²BROWN MEDICINE, BROWN UNIVERSITY, Riverside, RI
Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease…
Abstract Number: 0937 • ACR Convergence 2025
MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
Melodie Zaknoun¹, Doaa Tehawey¹, Baruh Polis¹ and Chaim Putterman², ¹Azrieli Faculty of Medicine, Safed, Israel, ²Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Of the 19 ACR case definitions for NPSLE, seven involve the peripheral nervous system. MRL/lpr mice spontaneously develop anti-dsDNA antibodies, nephritis, and skin disease,…
Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Sawyer May¹, Lynn Price¹ and Ryan Rex², ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Ioannis Parodis¹, Caroline Gordon², Joan Merrill³, Matthias Schneider⁴, Zahi Touma⁵, Teri Jimenez⁶, Thomas Morel⁷, Mina Nejati⁸, Christian Stach⁹, Christine de La Loge¹⁰ and Laurent arnaud¹¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶UCB, Raleigh, NC, ⁷UCB, Basel, Switzerland, ⁸Biogen, Cambridge, MA, ⁹UCB, Monheim am Rhein, Germany, ¹⁰UCB, Brussels, Belgium, ¹¹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…
Abstract Number: 0623 • ACR Convergence 2025
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Marco Martinez¹, Karen Roberts², Rosana Quintana³, Marina Scolnik⁴, Carmen Funes Soaje⁵, Paula Alba⁶, Veronica Saurit⁷, Mercedes Garcia⁸, GUILLERMO ARIEL BERBOTTO⁹, Inés Verónica Bellomio¹⁰, Mario Eduardo Kerzberg¹¹, Graciela Noemi Gomez¹², Cecilia Pisoni¹³, Vicente Juarez¹⁴, Ana Malvar¹⁵, Antonio Da Silva¹⁶, ODIRLEI MONTICIELO¹⁷, Henrique Mariz¹⁸, Francinne Ribeiro¹⁹, Eduardo Borba²⁰, Eloisa Bonfa²⁰, Edgard dos Reis-Neto²¹, Iris Guerra Herrera²², Maria Loreto Massardo²³, Gustavo Aroca-Martínez²⁴, Lorena Gómez Escorcia²⁵, Carlos Alberto Cañas²⁶, Gerardo Quintana-Lopez²⁷, Carlos Toro-Gutierrez²⁸, Mario Moreno Alvarez²⁹, MIGUEL SAAVEDRA³⁰, Margarita Portela Hernández³¹, Hilda Fragoso-Loyo³², Luis H Silveira³³, Ignacio García-De la Torre³⁴, Carlos Abud-Mendoza³⁵, Jorge Antonio Esquivel Valerio³⁶, Maria Isabel Acosta³⁷, Astrid Paats³⁸, Claudia S. Mora-Trujillo³⁹, Manuel Ugarte-Gil⁴⁰, Armando Calvo⁴¹, Roberto Muñoz-Louis⁴², Martin Rebella⁴³, Alvaro Danza⁴⁴, José Gomez-Puerta⁴⁵, Federico Zazzetti⁴⁶, Ashley Orillion⁴⁷, Guillermo Pons-Estel³ and Ingris del Pilar Pelaez Ballestas⁴⁸, ¹HGSZ No ⁹, Instituto Mexicano del Seguro Social, San Luis Potosí, México, Rioverde, Mexico, ²Instituto de Investigación, Rosario, Argentina, Wyomissing, PA, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁷Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ¹⁰Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹¹Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹²Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Don Torcuato, Argentina, ¹³CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁴Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁵Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁶Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Holzkirchen, Germany, ¹⁷Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁸Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁹Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ²⁰Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²²Hospital del Salvador Santiago de Chile, Santiago, Chile, santiago, Chile, ²³Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁴Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁵Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁶Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁷Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogota, Colombia, ²⁸Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁹Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁰Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³¹Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁴Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁵Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁶Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁹Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Universidad Cientifica del Sur, Lima, Peru, ⁴¹Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴²Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴³Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴⁶Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁸Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico, Mexico, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Evidence from high-income countries suggests that socioeconomic status (SES) and environmental…
Abstract Number: 0607 • ACR Convergence 2025
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
Daniel Goldman¹, Andrea Fava², Laurence Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…
Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
CHEN-YU LEE¹, Sepehr Taghavi², Shangzhu Zhang³, Roopa Madhu⁴, Jasmine Shwetar⁵, Tyler O'Malley⁶, Daniel Goldman⁷, Peter Izmirly⁸, H Michael Belmont⁹, Richard Furie¹⁰, Noa Schwartz¹¹, Chaim Putterman¹², Jennifer Barnas¹³, Jennifer Anolik¹⁴, Sarah French¹⁵, Maria Dall'Era¹⁶, Judith James¹⁷, Joel Guthridge¹⁷, Jacob Vasquez¹⁸, Mike Nerenberg¹⁹, Andrew Concoff²⁰, Christine Schleif²¹, Kevin Wei²², Thomas Eisenhaure²³, Nir Hacohen²³, Rachael Bogle²⁴, Johann Gudjonsson²⁵, Lam Tsoi²⁵, Brad Rovin²⁶, Jill Buyon²⁷, Michelle Petri⁷ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Exagen Inc, Escondido, CA, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Brookline, MA, ⁵New York School of Medicine, Ann Arbor, MI, ⁶Exagen, Vista, CA, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰Division of Rheumatology, Northwell Health, Great Neck, NY, ¹¹Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ¹²Albert Einstein College of Medicine, Safed, Israel, ¹³University of Rochester, Rochester, NY, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵UCSF, Mill Valley, CA, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Exagen, Inc., Vista, CA, ¹⁹Exagen, DEL MAR, CA, ²⁰Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, ²¹Exagen, Carlsbad, CA, ²²Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²³Broad Institute, Cambridge, MA, ²⁴University of Michigan, Holland, OH, ²⁵University of Michigan, Ann Arbor, MI, ²⁶The Ohio State University, Columbus, OH, ²⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…
Abstract Number: 0772 • ACR Convergence 2025
Redefining When to Biopsy the Kidney in Patients with SLE
Michelle Petri¹, Andrea Fava², Mohamed Atta³, Avi Rosenberg³, Sanchit Sanyal³, Peter Izmirly⁴, Erin Carter⁵, Mala Masson⁶, Michael Belmont⁷, Jennifer Barnas⁸, Jennifer Anolik⁹, Brad Rovin¹⁰ and Jill Buyon⁴, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁷NYU Langone Health, New York, NY, ⁸University of Rochester, Rochester, NY, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰The Ohio State University, Columbus, OH
Background/Purpose: Current ACR, EULAR and KDIGO guidelines recommend kidney biopsy in SLE patients with urine protein to creatinine (UPCR) ratio of >= 0.50 g/g. However,…
Abstract Number: 0188 • ACR Convergence 2025
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Taylor Williamson¹, Emily Shantz¹, Susan Elliott¹, Christine Sperling², Karen H. Costenbader³ and May Choi⁴, ¹University of Waterloo, Waterloo, Canada, ²None, Calgary, Canada, ³Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].